Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 21;396(10263):1614-1616.
doi: 10.1016/S0140-6736(20)32318-7. Epub 2020 Nov 4.

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Roy M Anderson  1 , Carolin Vegvari  2 , James Truscott  2 , Benjamin S Collyer  2
Affiliations

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Roy M Anderson et al. Lancet. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Impact of vaccine efficacy and duration of protection on what percentage of the population must be vaccinated in the first year (A) and when the system approaches equilibrium in 2–3 years under continued vaccination (B) (A) The percentage of the population who must be vaccinated, pc(1) × 100, for the first year of vaccination as a function of vaccine efficacy, ε, and protection duration (D=1/γ2), for Ro=2·5. Here the fraction who must be vaccinated within 1 year, pc(1), is defined in the appendix. If the value is greater than 100%, vaccination must take place more frequently than annually. (B) The percentage requiring vaccination in the population once the system has reached a new equilibrium after a few years of mass vaccination, as a function of vaccine efficacy and protection duration, for Ro=2·5. Ro=basic reproduction number.
See this image and copyright information in PMC

References

    1. Bloom BR, Lambert PH. 2nd edn. Academic Press/Elsevier; London: 2016. The vaccine book.
    1. Ward H, Cooke G, Atchinson C. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. medRxiv. 2020 doi: 10.1101/2020.10.26.20219725. published online Oct 27. (preprint) - DOI
    1. Wajnberg A, Amanat F, Firpo A. Robust neutralizing antibodies to SARS-CovV-2 infection persist for months. Science. 2020 doi: 10.1126/science.abd772.8. published online Oct 28. - DOI - PMC - PubMed
    1. Ripperger TJ, Uhrlaub JL, Watanabe M. Orthogonal SARS-CoV-2 serological assays enable surveillance of low prevalence communities and reveal durable immunity. Immunity. 2020 doi: 10.1016/j.immuni.2020.10.004. published online Oct 13. - DOI - PMC - PubMed
    1. Addetia A, Crawford KHD, Dingens A. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020;58:e02107–e02120. - PMC - PubMed